Editorial Board
Ying Hu
Professor, Harbin Institute of Technology · China
Editorial leadership for International Journal of Oxygen Compounds
Research interests
- Investigate P53 Signaling
- Particularly To Dissect The Interactions Of P53 Family Members With Other Upstream Regulatory Proteins
- Such As Aspps
Biography
- Dr. Ying Hu, Ph.D.in cancer biology, now is a Professor of biology, PI of the Gene function Research Laboratory in the School of Life Science of Technology, Harbin Institute of Technology.
- She got his B. Sc in public health and then finished her Maser degree majoring in biochemistry and molecular biology. After that she finished her PhD training in cancer biology in the University College London.
- Dr. Hu worked in the University of Oxford for about 2 years for as a postdoctoral scientist before she went back to China and set up her own research team in 2012.
- Dr. Hu’s research interest is to investigate p53 signaling and particularly to dissect the interactions of p53 family members with other upstream regulatory proteins, such as ASPPs.
- Her group is focused on the translational and posttranslational regulatory mechanisms of ASPPs. Another paradigm of their work is to reveal p53-independent biological functions of ASPPs.
- The research in the lab is carried out at molecular and cellular levels using both cancer cells models and clinical human cancer tissue samples.
- The methods and technologies used in her current lab include in vitro cell culture, MTT, Western Blotting, FACS, RT-PCR, molecular cloning, soft agar assay and many other molecular and cellular tools.
- The goal of laboratory is to develop clinically relevant biomarkers and therapeutic targets for human malignancy diseases.
Selected publications
- Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications 2023 cited 280×
- SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation 2023 cited 103×
- A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth 2019 cited 90×
- The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells 2023 cited 71×
- A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia 2019 cited 42×
- A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers 2020 cited 42×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering IJO for your work?
This journal is guided by Ying Hu (Professor, Harbin Institute of Technology) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.